Ultragenyx Pharmaceutical (NASDAQ:RARE) is one of the 17 biotechnology stocks with more than 50% upside.
On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, who maintained a Buy rating on the stock. The analyst’s estimate leads to a promising upside potential of more than 155% from the prevailing level.
Pressmaster/Shutterstock.com
Selvaraju attributed his views to the company’s impressive rare disease pipeline and expected regulatory milestones. He also highlighted on-schedule BLA resubmission for UX111, which includes extended clinical data showing sustained neurologic benefits and biomarker improvements. The filing also includes an adequate safety profile for Sanfilippo syndrome type A, which does not have any approved therapies. The analyst is optimistic about the company achieving profitability as early as 2027, which reflects favorably on its attractive risk-reward profile.
On January 28, Ultragenyx Pharmaceutical (NASDAQ:RARE) was assigned an Overweight rating by Barclays analyst Eliana Merle. She estimated a target price of $44, which yields more than 87% upside potential. Merle anticipates a more favorable outlook for biotech stocks, supported by robust fundamentals and forecasted continued mergers and acquisitions activity.
Ultragenyx Pharmaceutical (NASDAQ:RARE) develops novel therapies, with a focus on identifying, acquiring, and commercializing products for rare and ultra-rare genetic diseases. It places strong emphasis on gene therapy and covers the various stages of clinical trials. The company is currently experiencing high cash burn, with the aim of becoming profitable from 2027 onward.
While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
Disclosure: None. This article is originally published at Insider Monkey.
